The algorithm is found as a valid metric for risk stratifying specific target populations for future pathological events, including cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure.

It will also help diabetics for the presence of diabetic autonomic neuropathy, trauma victims for imminent death absent immediate lifesaving intervention, and ICU patients for mortality risk stratification.

ZOLL will add Vicor’s PD2i technology in existing and future products to allow real time analysis of patient physiological information and risk prediction to facilitate earlier intervention in patients and prevent serious events.